AI Article Synopsis
Article Abstract
Background: Children with short bowel syndrome (SBS) frequently struggle with malabsorption and poor growth. The intestinal microbiota plays an important role in gut function, and children with SBS have known deficiencies in some commensal gut microbes. One strategy to enhance the gut microbiota is by taking probiotics. However, the efficacy of this approach is not well established. We hypothesized that probiotic supplementation would result in increased levels of the supplemented bacteria and improved growth.
Materials And Methods: Children with SBS who had weaned from parenteral nutrition but with suboptimal growth were randomized to receive probiotics (Lactobacillus rhamnosus and Lactobacillus johnsonii) or placebo daily for 2 mo. The gut microbiota from monthly stool samples were compared between groups using 16S ribosomal ribonucleic acid sequencing and quantitative polymerase chain reaction. Growth between groups was also compared. Statistical analysis was completed using Mann-Whitney, Kruskal-Wallis, and chi-square tests as appropriate.
Results: Eighteen children with SBS completed the study (n = 9 per group). There were no significant changes to the major bacterial families in either group. Median relative abundance of Lactobacillus did not differ between groups at baseline or at the end of the study (7.67 versus 13.23, P = 0.523 and 1.93 versus 15.8, P = 0.161). Median z scores for weight and length did not differ between groups at the beginning or end of the study.
Conclusions: The efficacy of daily probiotic use in children with intestinal failure is unknown. In this study, Lactobacillus probiotics did not result in a predictable change to the fecal microbiota or overall growth compared with placebo in these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jss.2020.01.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Lactoferrin-Responsive Formulation Anchoring around Inflammatory Bowel Region for IBD Therapy.
Adv Healthc Mater
December 2024
Department of Oncology, The Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Oral formulation is the ideal treatment method for inflammatory bowel disease (IBD) therapy, but the mucosal damage and diarrhea symptoms impede the drug retention around the inflammatory region, severely limiting IBD therapeutic efficacy. To address this, an oral astaxanthin (Ast) precise delivery formulation is developed with the selective Ast anchoring around the inflammatory region by the novel lactoferrin (LF)-responsive flocculation. This formulation also heightens the apparent solubility of Ast with the minimized edible safety risks for the edible raw materials.
View Article and Find Full Text PDFAn Oral HS Responsive CuO Nanozyme Platform with Strong ROS/HS Scavenging Capacity for the Treatment of Colitis.
ACS Appl Mater Interfaces
December 2024
Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Inflammatory bowel disease involves excess reactive oxygen species (ROS) and hydrogen sulfide (HS) at inflammatory sites. Nanozyme-mediated ROS and HS scavenging therapy is promising for colitis treatment. Here, we synthesized a multiple ROS scavenging CuO nanoparticle and first explored its HS scavenging capacity.
View Article and Find Full Text PDFVaccine protection of broilers against various doses of wild-type Typhimurium and changes in gut microbiota.
Vet Q
December 2025
School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, Australia.
This study evaluated the impact of vaccine diluents (peptone or water) on the protective effects of Typhimurium (. Typhimurium) vaccine. Vaccinated broilers were challenged with different doses of wild-type .
View Article and Find Full Text PDFMaternal Lactobacillus johnsonii supplementation attenuates hyperoxia-induced lung injury in neonatal mice through microbiota regulation.
Pediatr Neonatol
December 2024
Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan; Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; TMU Research Center for Digestive Medicine, Taipei Medical University, Taiwan. Electronic address:
Background: Supplemental oxygen impairs lung development in premature infants with respiratory distress. This study investigated the effects of maternal Lactobacillus johnsonii supplementation on hyperoxia-induced lung injury in neonatal mice.
Methods: Pregnant C57BL/6 mice received L.
The causal relationship between gut microbiota and preterm birth: a two-sample Mendelian randomization study.
J Matern Fetal Neonatal Med
December 2025
Department of Clinical Laboratory, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Background: Preterm birth, a significant global health concern, has been associated with alterations in the gut microbiota. However, the causal nature of this relationship remains uncertain due to the limitations inherent in observational studies.
Purpose: To investigate the potential causal relationship between gut microbiota imbalances and preterm birth.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!